Biogen quarterly profit jumps on higher Spinraza sales
April 24 (Reuters) - Drug developer Biogen Inc reported a 57 percent jump in quarterly profit on Tuesday, helped by higher sales of its spinal muscular atrophy drug, Spinraza.
Net income attributable to shareholders rose to $1.17 billion in the first quarter ended March 31, or $5.54 per share, from $747.6 million or $3.46 a share, a year earlier.
Revenue rose to $3.13 billion from $2.81 billion. (Reporting by Mrinalini Krothapalli; Editing by Amrutha Gayathri)